| 3. |
- Zhang, Wei, et al.
(author)
-
Lifetime measurements of excited states in 169,171,173Os : Persistence of anomalous B(E2) ratios in transitional rare earth nuclei in the presence of a decoupled i13/2 valence neutron
- 2021
-
In: Physics Letters B. - : Elsevier BV. - 0370-2693 .- 1873-2445. ; 820
-
Journal article (peer-reviewed)abstract
- Lifetimes of low-lying excited states in the νi13/2+ bands of the neutron-deficient osmium isotopes 169,171,173Os have been measured for the first time using the recoil-distance Doppler shift and recoil-isomer tagging techniques. An unusually low value is observed for the ratio B(E2;21/2+→17/2+)/B(E2;17/2+→13/2+) in 169Os, similar to the “anomalously” low values of the ratio B(E2;41+→21+)/B(E2;21+→0gs+) previously observed in several transitional rare-earth nuclides with even numbers of neutrons and protons, including the neighbouring 168,170Os. Furthermore, the evolution of B(E2;21/2+→17/2+)/B(E2;17/2+→13/2+) with increasing neutron number in the odd-mass isotopic chain 169,171,173Os is observed to follow the same trend as observed previously in the even-even Os isotopes. These findings indicate that the possible quantum phase transition from a seniority conserving structure to a collective regime as a function of neutron number suggested for the even-even systems is maintained in these odd-mass osmium nuclei, with the odd valence neutron merely acting as a “spectator”. As for the even-even nuclei, the phenomenon is highly unexpected for nuclei that are not situated near closed shells.
|
|
| 4. |
- Kar, Rohan, et al.
(author)
-
The FBXW7-NOTCH interactome : A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues
- 2021
-
In: Cancer Reports. - : John Wiley & Sons. - 2573-8348. ; 4:4
-
Research review (peer-reviewed)abstract
- Background Ubiquitin ligases or E3 ligases are well programmed to regulate molecular interactions that operate at a post-translational level. Skp, Cullin, F-box containing complex (or SCF complex) is a multidomain E3 ligase known to mediate the degradation of a wide range of proteins through the proteasomal pathway. The three-dimensional domain architecture of SCF family proteins suggests that it operates through a novel and adaptable "super-enzymatic" process that might respond to targeted therapeutic modalities in cancer. Recent findings Several F-box containing proteins have been characterized either as tumor suppressors (FBXW8, FBXL3, FBXW8, FBXL3, FBXO1, FBXO4, and FBXO18) or as oncogenes (FBXO5, FBXO9, and SKP2). Besides, F-box members like beta TrcP1 and beta TrcP2, the ones with context-dependent functionality, have also been studied and reported. FBXW7 is a well-studied F-box protein and is a tumor suppressor. FBXW7 regulates the activity of a range of substrates, such as c-Myc, cyclin E, mTOR, c-Jun, NOTCH, myeloid cell leukemia sequence-1 (MCL1), AURKA, NOTCH through the well-known ubiquitin-proteasome system (UPS)-mediated degradation pathway. NOTCH signaling is a primitive pathway that plays a crucial role in maintaining normal tissue homeostasis. FBXW7 regulates NOTCH protein activity by controlling its half-life, thereby maintaining optimum protein levels in tissue. However, aberrations in the FBXW7 or NOTCH expression levels can lead to poor prognosis and detrimental outcomes in patients. Therefore, the FBXW7-NOTCH axis has been a subject of intense study and research over the years, especially around the interactome's role in driving cancer development and progression. Several studies have reported the effect of FBXW7 and NOTCH mutations on normal tissue behavior. The current review attempts to critically analyze these mutations prognostic value in a wide range of tumors. Furthermore, the review summarizes the recent findings pertaining to the FBXW7 and NOTCH interactome and its involvement in phosphorylation-related events, cell cycle, proliferation, apoptosis, and metastasis. Conclusion The review concludes by positioning FBXW7 as an effective diagnostic marker in tumors and by listing out recent advancements made in cancer therapeutics in identifying protocols targeting the FBXW7-NOTCH aberrations in tumors.
|
|
